Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise

(Society of Nuclear Medicine and Molecular Imaging) In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival. The study is reported in The Journal of Nuclear Medicine's July featured article of the month.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news